Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.67 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459293 | 1.00 | TACR1 (0.71) | TACR1MAPTKMT2AMEN1HCRTR1 | |
| SCHEMBL14815316 | 0.89 | P2RY14 (0.69) | TACR1MAPTKMT2AMEN1TP53 | |
| SCHEMBL1458374 | 0.89 | P2RY14 (0.69) | TACR1MAPTKMT2AMEN1TP53 | |
| SCHEMBL16618053 | 0.85 | KMT2A (0.64) | TACR1MAPTKMT2AMEN1HCRTR1 | |
| SCHEMBL16618054 | 0.85 | KMT2A (0.64) | TACR1MAPTKMT2AMEN1HCRTR1 | |
| SCHEMBL21001593 | 0.84 | KMT2A (0.76) | TACR1MAPTKMT2AMEN1HCRTR1 | |
| SCHEMBL21001592 | 0.84 | KMT2A (0.76) | TACR1MAPTKMT2AMEN1HCRTR1 | |
| SCHEMBL27703075 | 0.84 | KMT2A (0.71) | TACR1MAPTKMT2AMEN1HCRTR1 | |
| SCHEMBL9257911 | 0.83 | TACR1 (1.00) | TACR1MAPTKMT2AMEN1TP53 | |
| SCHEMBL21001594 | 0.83 | KMT2A (0.81) | TACR1MAPTKMT2AMEN1HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822698-B2 | Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family | UNIVERSITE D'AIX-MARSEILLE (FR) | 2014-09-02 | — | — | US | disclosed |
| US-20130085143-A1 | AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY | UNIVERSITE D'AIX-MARSEILLE (FR) | 2013-04-04 | — | — | US | disclosed |
| EP-2483280-A1 | NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY | Université d'Aix-Marseille (FR) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011036303-A1 | NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY | UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II (FR) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085143-A1 | AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY | MET, HGFAC, HRAS | TACR1 4287/4885MAPT 4123/4885KMT2A 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.